Novelion (NVLN-T) Stock Predictions - Stockchase
WATCH LIST
191
Novelion (NVLN-T)

ON STOCKCHASE SINCE Oct 2000

Formerly QLT. Merged with Aegeron Dec 2016)

Voluntarilly delisted (May 2017)

biotechnology/pharmaceutical

Novelion

NVLN-T

7 watching          
Join the Discussion

Novelion (NVLN-T) SAVE Dec, 31, 1969, 7:00 pm

0.00 0 (100%)

This company is not ACTIVE.

What the experts are saying about NVLN-T



  • All
  • Filtered
Signal Opinion Expert
BUY on WEAKNESS
Novelion(NVLN-T) 

August 7, 2009

(Market Call Minute.) Could see it as a Buy but would like it at a cheaper price.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(Market Call Minute.) Could see it as a Buy but would like it at a cheaper price.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$4.100
Owned Owned
Unknown

SELL
Novelion(NVLN-T) 

October 23, 2007

The future isn't bright. Losing market share with their main product. Suggests tax loss selling.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The future isn't bright. Losing market share with their main product. Suggests tax loss selling.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Baskin

President, Baskin Wealth Manage...

Price Price
$4.350
Owned Owned
No

DON'T BUY
Novelion(NVLN-T) 

December 22, 2005

Has been a very disappointing stock. Had problems with its major drug because of competition. The problem with the Canadian drug sector is that it tends to be one or two drug dependent.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Has been a very disappointing stock. Had problems with its major drug because of competition. The problem with the Canadian drug sector is that it tends to be one or two drug dependent.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Laura Wallace

Managing D, Coleford Investment ...

Price Price
$7.040
Owned Owned
No

SELL
Novelion(NVLN-T) 

November 11, 2005

The biggest threat to any business is a competing technology or product. That's what the market thinks is happening here.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The biggest threat to any business is a competing technology or product. That's what the market thinks is happening here.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$8.100
Owned Owned
No

DON'T BUY
Novelion(NVLN-T) 

September 29, 2005

The drug companys are due for a slow turn around. Had a lot of problems with the FDA. Lots of competition going to happen.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The drug companys are due for a slow turn around. Had a lot of problems with the FDA. Lots of competition going to happen.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Zechner

Chairman, J. Zechner & Assoc...

Price Price
$9.000
Owned Owned
No

DON'T BUY
Novelion(NVLN-T) 

August 11, 2005

Looks cheap at 10 X earnings. Have a drug that is photo-activated, but competitors have come which has pulled the stock down. Bought a company that had an acne cream, but because of labeling problems, it's another year or two away.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Looks cheap at 10 X earnings. Have a drug that is photo-activated, but competitors have come which has pulled the stock down. Bought a company that had an acne cream, but because of labeling problems, it's another year or two away.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Higgins,

Vice Presi, Sentry Select Capita...

Price Price
$10.000
Owned Owned
No

WAIT
Novelion(NVLN-T) 

June 15, 2005

Likes the company from the standpoint of a product. Thinks they are still way ahead of the competitors, particularily in the eye treatment area. Have expanded their product base which is not bad. Market has been unmerciful to this stock. Hopefully it has hit a bottom, but would wait to see if the stock can work its way through.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Likes the company from the standpoint of a product. Thinks they are still way ahead of the competitors, particularily in the eye treatment area. Have expanded their product base which is not bad. Market has been unmerciful to this stock. Hopefully it has hit a bottom, but would wait to see if the stock can work its way through.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Cockfield

Managing D, Northland Wealth Man...

Price Price
$11.890
Owned Owned
Yes

DON'T BUY
Novelion(NVLN-T) 

June 6, 2005

A one trick pony. Visudine is great, but they haven't really gone beyond this. Getting new competition.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A one trick pony. Visudine is great, but they haven't really gone beyond this. Getting new competition.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$12.590
Owned Owned
No

SELL
Novelion(NVLN-T) 

May 25, 2005

Their treatment of macular degeneration only treats the latter stage while the competition is going after the initial stage. This company is like a one trick pony. Major competition is coming in.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Their treatment of macular degeneration only treats the latter stage while the competition is going after the initial stage. This company is like a one trick pony. Major competition is coming in.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$13.020
Owned Owned
No

DON'T BUY
Novelion(NVLN-T) 

April 11, 2005

This is bottom fishing, bargain hunting on a stock that is below the 200 day moving average. This stock is really base building. The stock is not participating in this bull market, so will possibly sit out the next bear market and you may have to wait for the next bull market which could be 2 years away.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
This is bottom fishing, bargain hunting on a stock that is below the 200 day moving average. This stock is really base building. The stock is not participating in this bull market, so will possibly sit out the next bear market and you may have to wait for the next bull market which could be 2 years away.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ron Meisels

President, P & C Holdings...

Price Price
$15.370
Owned Owned
No

DON'T BUY
Novelion(NVLN-T) 

March 10, 2005

Perhaps should sell... recovery could be 6,8,9 months down the road. Could be dead money.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Perhaps should sell... recovery could be 6,8,9 months down the road. Could be dead money.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Cockfield

Managing D, Northland Wealth Man...

Price Price
$15.630
Owned Owned
Yes

WEAK BUY
Novelion(NVLN-T) 

March 9, 2005

Sold his holdings last year and hasn't come back to it yet, but is watching closely. Visudyne now has growing competition. Didn't like the Attrix acquisition and not sure if they will get any growth from it. Has good cash position, assets and core product.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Sold his holdings last year and hasn't come back to it yet, but is watching closely. Visudyne now has growing competition. Didn't like the Attrix acquisition and not sure if they will get any growth from it. Has good cash position, assets and core product.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Zechner

Chairman, J. Zechner & Assoc...

Price Price
$15.360
Owned Owned
No

DON'T BUY
Novelion(NVLN-T) 

February 15, 2005

You have to wait to see some strength come back in the pharmaceuticals. They were formerly a one drug company, but with their recent acquisition, it makes them a little bit more interesting, but there is still no buying going on.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
You have to wait to see some strength come back in the pharmaceuticals. They were formerly a one drug company, but with their recent acquisition, it makes them a little bit more interesting, but there is still no buying going on.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$18.810
Owned Owned
No

DON'T BUY
Novelion(NVLN-T) 

February 14, 2005

Visudyne has done really well but competition is coming from Pfizer. Will lose a little bit of market share for awhile and growth will slow down. In the end they may win the battle, but in the short term it will be difficult. Not happy with the recent merger with Atrix Laboritories. Felt they had a weak pipeline.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Visudyne has done really well but competition is coming from Pfizer. Will lose a little bit of market share for awhile and growth will slow down. In the end they may win the battle, but in the short term it will be difficult. Not happy with the recent merger with Atrix Laboritories. Felt they had a weak pipeline.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Zechner

Chairman, J. Zechner & Assoc...

Price Price
$18.240
Owned Owned
No

WAIT
Novelion(NVLN-T) 

February 1, 2005

Because of the acquisition they just did, would like to see a couple of quarters of results out of the new drugs that are in that acquisition. Has seen some weakness with a 10/15% decline in sales.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Because of the acquisition they just did, would like to see a couple of quarters of results out of the new drugs that are in that acquisition. Has seen some weakness with a 10/15% decline in sales.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Mark Jackson, C

President , Aegon Capital Manage...

Price Price
$19.940
Owned Owned
No

Showing 1 to 15 of 190 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days